JP7398959B2 - 向上した免疫抑制作用を有する間葉系前駆または幹細胞 - Google Patents

向上した免疫抑制作用を有する間葉系前駆または幹細胞 Download PDF

Info

Publication number
JP7398959B2
JP7398959B2 JP2019560259A JP2019560259A JP7398959B2 JP 7398959 B2 JP7398959 B2 JP 7398959B2 JP 2019560259 A JP2019560259 A JP 2019560259A JP 2019560259 A JP2019560259 A JP 2019560259A JP 7398959 B2 JP7398959 B2 JP 7398959B2
Authority
JP
Japan
Prior art keywords
cells
cell
mlpscs
mesenchymal progenitor
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019560259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518260A (ja
Inventor
シルヴィウ・イテスク
ポール・シモンズ
Original Assignee
メゾブラスト・インターナショナル・エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901633A external-priority patent/AU2017901633A0/en
Application filed by メゾブラスト・インターナショナル・エスアーエールエル filed Critical メゾブラスト・インターナショナル・エスアーエールエル
Publication of JP2020518260A publication Critical patent/JP2020518260A/ja
Priority to JP2023173584A priority Critical patent/JP7787130B2/ja
Application granted granted Critical
Publication of JP7398959B2 publication Critical patent/JP7398959B2/ja
Priority to JP2025230822A priority patent/JP2026034487A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019560259A 2017-05-04 2018-05-04 向上した免疫抑制作用を有する間葉系前駆または幹細胞 Active JP7398959B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023173584A JP7787130B2 (ja) 2017-05-04 2023-10-05 向上した免疫抑制作用を有する間葉系前駆または幹細胞
JP2025230822A JP2026034487A (ja) 2017-05-04 2025-12-04 向上した免疫抑制作用を有する間葉系前駆または幹細胞

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2017901633 2017-05-04
AU2017901633A AU2017901633A0 (en) 2017-05-04 Potency assay for immunosuppression
AU2017901636A AU2017901636A0 (en) 2017-05-04 Method for treating Graft versus Host Disease (GVHD)
AU2017901636 2017-05-04
AU2018900551A AU2018900551A0 (en) 2018-02-21 Potency assay for immunosuppression II
AU2018900551 2018-02-21
PCT/EP2018/061503 WO2018202853A1 (en) 2017-05-04 2018-05-04 Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023173584A Division JP7787130B2 (ja) 2017-05-04 2023-10-05 向上した免疫抑制作用を有する間葉系前駆または幹細胞

Publications (2)

Publication Number Publication Date
JP2020518260A JP2020518260A (ja) 2020-06-25
JP7398959B2 true JP7398959B2 (ja) 2023-12-15

Family

ID=62222586

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019560259A Active JP7398959B2 (ja) 2017-05-04 2018-05-04 向上した免疫抑制作用を有する間葉系前駆または幹細胞
JP2023173584A Active JP7787130B2 (ja) 2017-05-04 2023-10-05 向上した免疫抑制作用を有する間葉系前駆または幹細胞
JP2025230822A Pending JP2026034487A (ja) 2017-05-04 2025-12-04 向上した免疫抑制作用を有する間葉系前駆または幹細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023173584A Active JP7787130B2 (ja) 2017-05-04 2023-10-05 向上した免疫抑制作用を有する間葉系前駆または幹細胞
JP2025230822A Pending JP2026034487A (ja) 2017-05-04 2025-12-04 向上した免疫抑制作用を有する間葉系前駆または幹細胞

Country Status (10)

Country Link
US (1) US20200325450A1 (https=)
EP (2) EP4137562A1 (https=)
JP (3) JP7398959B2 (https=)
KR (2) KR102660506B1 (https=)
CN (1) CN110753751A (https=)
AU (2) AU2018262788B2 (https=)
BR (1) BR112019022901A2 (https=)
CA (1) CA3062112A1 (https=)
SG (1) SG11201909856XA (https=)
WO (1) WO2018202853A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023174760A (ja) * 2017-05-04 2023-12-08 メゾブラスト・インターナショナル・エスアーエールエル 向上した免疫抑制作用を有する間葉系前駆または幹細胞

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
KR20220143092A (ko) * 2020-02-19 2022-10-24 메조블라스트 인터내셔널 에스에이알엘 만성 이식편 대 숙주 질환의 치료 방법
JP7793284B2 (ja) * 2020-03-02 2026-01-05 株式会社ガイアバイオメディシン 高活性ｎｋ細胞の処理方法
JP2023530098A (ja) * 2020-06-11 2023-07-13 メゾブラスト・インターナショナル・エスアーエールエル 間葉系前駆細胞又は幹細胞の３ｄ培養
AU2021323475A1 (en) * 2020-08-10 2023-04-13 Mesoblast International Sarl A composition comprising mesenchymal precursor or stem cells and their use
CN112444479B (zh) * 2021-02-01 2021-05-07 宁波大学 基于并行处理技术的单细胞质谱分析系统及方法
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途
US20250032552A1 (en) * 2021-12-23 2025-01-30 Mesoblast International Sárl Method of treating severe graft versus host disease
CA3260880A1 (en) * 2022-07-05 2024-01-11 Mesoblast International Sarl CRYOPROVERTED INTERMEDIATE AND BIOLOGICAL ACTIVITY TEST FOR IT
KR20250049337A (ko) 2022-08-09 2025-04-11 엑손모빌 케미칼 패턴츠 인코포레이티드 디페닐실란 가교 c1 대칭 촉매의 제조 방법 및 이로부터 제조된 중합체
WO2024168161A1 (en) * 2023-02-08 2024-08-15 Mesoblast International Sarl Potency assay and manufacturing method
WO2025196663A1 (en) * 2024-03-19 2025-09-25 Mesoblast International Sarl Potency assay and manufacturing method ii
CN118147232B (zh) * 2024-05-09 2024-07-19 中国人民解放军联勤保障部队第九二〇医院 一种过表达tps1间充质干细胞的构建方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
WO1994026877A1 (en) 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
US6566051B1 (en) 1999-01-15 2003-05-20 Medtox Scientific, Inc. Lateral flow test strip
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
CN101248171B (zh) 2005-04-12 2015-11-25 迈索布拉斯特股份有限公司 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
KR101891260B1 (ko) * 2010-07-02 2018-08-24 메소블라스트, 아이엔씨. T-세포 매개된 면역 질환의 치료
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
KR20150016117A (ko) * 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
SG11201607925SA (en) * 2014-04-07 2016-10-28 Mesoblast Internat Sarl Improved stem cell composition
EP3236977B1 (en) * 2014-12-23 2023-06-21 Mesoblast International Sàrl Method for treating heart failure
SG11201909856XA (en) 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Experimental Hematology，2002年，Vol.30，pp.42-48
Stem Cell Reviews and Reports ，2011年，Vol.7，pp.381-393

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023174760A (ja) * 2017-05-04 2023-12-08 メゾブラスト・インターナショナル・エスアーエールエル 向上した免疫抑制作用を有する間葉系前駆または幹細胞
JP7787130B2 (ja) 2017-05-04 2025-12-16 メゾブラスト・インターナショナル・エスアーエールエル 向上した免疫抑制作用を有する間葉系前駆または幹細胞

Also Published As

Publication number Publication date
JP2020518260A (ja) 2020-06-25
WO2018202853A1 (en) 2018-11-08
EP4137562A1 (en) 2023-02-22
KR102884611B1 (ko) 2025-11-12
SG11201909856XA (en) 2019-11-28
KR102660506B1 (ko) 2024-04-25
EP3619294A1 (en) 2020-03-11
US20200325450A1 (en) 2020-10-15
AU2018262788B2 (en) 2024-08-15
KR20200003044A (ko) 2020-01-08
JP2026034487A (ja) 2026-02-27
JP7787130B2 (ja) 2025-12-16
JP2023174760A (ja) 2023-12-08
BR112019022901A2 (pt) 2020-05-19
CA3062112A1 (en) 2018-11-08
AU2024227344A1 (en) 2024-10-31
CN110753751A (zh) 2020-02-04
KR20240056790A (ko) 2024-04-30
AU2018262788A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
JP7787130B2 (ja) 向上した免疫抑制作用を有する間葉系前駆または幹細胞
US20260079159A1 (en) Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
EP2578677A1 (en) Method of treating autoimmune disease with mesenchymal stem cells
JP6315989B2 (ja) Ｔ細胞性免疫不全の治療法
WO2018229163A1 (en) Methods of activating v delta 2 negative gamma delta t cells
KR20180033537A (ko) Pd-l1 발현 조혈 줄기 세포 및 용도
US20130028890A1 (en) Method for detecting regulatory t cells using expression of folate receptor 4 as indicator, method for treating diseases using the detection method, pharmaceutical composition for immunostimulation, and method for treating diseases using the composition
JP6563999B2 (ja) リウマチ性疾患を予防または治療する方法
KR102009056B1 (ko) 조골세포 기능의 향상방법
US20210269768A1 (en) Neonatal stromal cells having low mhc-i expression and uses therof
KR20250034958A (ko) 저온보존된 중간체 및 그에 대한 효력 검정
HK40088319A (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
JP2024512029A (ja) Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
CN117480246A (zh) 用于t细胞共培养物效力测定和配合细胞疗法产品使用的方法和组合物
JP2026504544A (ja) 効力アッセイ、及び製造方法
Kara Analysis of Lymphocytes with T regulatory Phenotype in Kidney Allografts of Saint-Petersburg

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230314

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231005

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231205

R150 Certificate of patent or registration of utility model

Ref document number: 7398959

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150